EMEA-000431-PIP01-08-M12
Key facts
| Invented name |
|
| Active substance |
|
| Therapeutic area |
Pneumology-allergology
|
| Decision number |
P/0092/2021
|
| PIP number |
EMEA-000431-PIP01-08-M12
|
| Pharmaceutical form(s) |
Inhalation powder, pre-dispensed
|
| Condition(s) / indication(s) |
Treatment of asthma
|
| Route(s) of administration |
Inhalation use
|
| Contact for public enquiries |
Glaxo Group Limited
E-mail: eu.paediatrics-plans@gsk.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|